Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil
- PMID: 23224978
- PMCID: PMC3596500
- DOI: 10.1007/s11095-012-0937-8
Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil
Abstract
Purpose: To determine the contribution of intestinal PepT1 on the permeability and oral absorption of the β-lactam antibiotic drug cefadroxil.
Methods: The effective permeability (P eff ) of cefadroxil was evaluated in wild-type and PepT1 knockout mice following in situ single-pass intestinal perfusions. The plasma concentration-time profiles of cefadroxil were also examined after oral gavage.
Results: The P eff (cm/s) of cefadroxil in wild-type mice was 0.49 × 10(-4) in duodenum, 0.80 × 10(-4) in jejunum, 0.88 × 10(-4) in ileum and 0.064 × 10(-4) in colon. The P eff (cm/s) in PepT1 knockout mice was significantly reduced in small intestine, but not in colon, as shown by values of 0.003 × 10(-4), 0.090 × 10(-4), 0.042 × 10(-4) and 0.032 × 10(-4), respectively. Jejunal uptake of cefadroxil was saturable (Km = 2-4 mM) and significantly attenuated by the sodium-proton exchange inhibitor 5-(N,N-dimethyl)amiloride. Jejunal permeability of cefadroxil was not affected by L-histidine, glycine, cephalothin, p-aminohippurate or N-methylnicotinamide. In contrast, cefadroxil permeability was significantly reduced by glycylproline, glycylsarcosine, or cephalexin. Finally, PepT1 ablation resulted in 23-fold reductions in peak plasma concentrations and 14-fold reductions in systemic exposure of cefadroxil after oral dosing.
Conclusions: The findings are definitive in demonstrating that PepT1 is the major transporter responsible for the small intestinal permeability of cefadroxil as well as its enhanced oral drug performance.
Figures









Similar articles
-
Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.Drug Metab Dispos. 2013 Mar;41(3):608-14. doi: 10.1124/dmd.112.049239. Epub 2012 Dec 21. Drug Metab Dispos. 2013. PMID: 23264448 Free PMC article.
-
Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice.Biochem Pharmacol. 2016 May 1;107:81-90. doi: 10.1016/j.bcp.2016.03.008. Epub 2016 Mar 12. Biochem Pharmacol. 2016. PMID: 26979860 Free PMC article.
-
In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.Pharm Res. 2013 Nov;30(11):2931-9. doi: 10.1007/s11095-013-1168-3. Pharm Res. 2013. PMID: 23959853 Free PMC article.
-
Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance.Curr Drug Metab. 2013 Jul;14(6):675-87. doi: 10.2174/1389200211314060004. Curr Drug Metab. 2013. PMID: 23869811 Review.
-
[Active drug delivery by heterologous expression of membrane transporters].Yakugaku Zasshi. 2003 Jun;123(6):413-22. doi: 10.1248/yakushi.123.413. Yakugaku Zasshi. 2003. PMID: 12822485 Review. Japanese.
Cited by
-
The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid.Br J Pharmacol. 2016 Jan;173(1):167-76. doi: 10.1111/bph.13356. Epub 2015 Nov 25. Br J Pharmacol. 2016. PMID: 26444978 Free PMC article.
-
Integrating the gut microbiome and pharmacology.Sci Transl Med. 2024 Jan 31;16(732):eadg8357. doi: 10.1126/scitranslmed.adg8357. Epub 2024 Jan 31. Sci Transl Med. 2024. PMID: 38295186 Free PMC article. Review.
-
In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model.AAPS PharmSciTech. 2024 May 7;25(5):100. doi: 10.1208/s12249-024-02811-z. AAPS PharmSciTech. 2024. PMID: 38714602
-
Development and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1.Mol Pharm. 2014 Oct 6;11(10):3737-46. doi: 10.1021/mp500497p. Epub 2014 Sep 2. Mol Pharm. 2014. PMID: 25148225 Free PMC article.
-
Effect of transporter inhibition on the distribution of cefadroxil in rat brain.Fluids Barriers CNS. 2014 Nov 14;11(1):25. doi: 10.1186/2045-8118-11-25. eCollection 2014. Fluids Barriers CNS. 2014. PMID: 25414790 Free PMC article.
References
-
- Daniel H, Spanier B, Kottra G, Weitz D. From bacteria to man: archaic proton-dependent peptide transporters at work. Physiol. 2006;21:93–102. - PubMed
-
- Rubio-Aliaga I, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica. 2008;38:1022–1042. - PubMed
-
- Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008;60:543–585. - PubMed
-
- Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 1994;368:563–566. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical